Sagimet Biosciences
SGMT
About: Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Employees: 14
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
98% more capital invested
Capital invested by funds: $44.9M [Q1] → $89M (+$44.1M) [Q2]
77% more call options, than puts
Call options by funds: $3.95M | Put options by funds: $2.24M
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
8% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 26
4% less funds holding
Funds holding: 70 [Q1] → 67 (-3) [Q2]
6.84% less ownership
Funds ownership: 44.9% [Q1] → 38.06% (-6.84%) [Q2]
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Wedbush
Yun Zhong
|
$28
|
Outperform
Initiated
|
11 Aug 2025 |
|
HC Wainwright & Co.
Brandon Folkes
|
$29
|
Buy
Assumed
|
7 Aug 2025 |
|
Canaccord Genuity
Edward Nash
|
$28
|
Buy
Initiated
|
24 Jul 2025 |
Financial journalist opinion
Based on 6 articles about SGMT published over the past 30 days
